← Back to Search

Ropivacaine for Gender Dysphoria

Phase 4
Waitlist Available
Led By Esther Kim, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 week post operative
Awards & highlights

Study Summary

This study is evaluating whether a nerve block can reduce pain and opioid consumption in patients undergoing gender-affirmation breast surgery.

Eligible Conditions
  • Gender Dysphoria
  • Opioid Use Disorder
  • Postoperative Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~intraoperative
This trial's timeline: 3 weeks for screening, Varies for treatment, and intraoperative for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Comparison of Post Operative Pain Scores
Secondary outcome measures
Comparison of Intra Operative Narcotic Requirements
Comparison of Post Operative Narcotic Requirements

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: RopivacaineExperimental Treatment1 Intervention
Intervention group will receive an injection of 20ml of 0.2% Ropivacaine between the pectoralis minor and serratus anterior muscles bilaterally and 10ml of 0.2% Ropivacaine between the pectoralis minor and pectoralis major muscles bilaterally (Not to exceed 225mg or 3.5mg/kg).
Group II: SalinePlacebo Group1 Intervention
Control group will receive an injection of 20ml of saline between the pectoralis minor and serratus anterior muscles bilaterally and 10ml of saline between the pectoralis minor and pectoralis major muscles bilaterally.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ropivacaine 0.2% Injectable Solution
2021
Completed Phase 4
~530

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,500 Previous Clinical Trials
15,236,421 Total Patients Enrolled
1 Trials studying Gender Dysphoria
3 Patients Enrolled for Gender Dysphoria
Esther Kim, MDPrincipal InvestigatorUniversity of California, San Francisco
2 Previous Clinical Trials
1,150 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Regional Anesthesia and Pain MedicineJournal
Pectoral Nerves I and II Blocks in Multimodal Analgesia for Breast Cancer Surgery
Bashandy, Ghada Mohammad Nabih, and Dina Nabil Abbas. 2015. “Pectoral Nerves I and II Blocks in Multimodal Analgesia for Breast Cancer Surgery”. Regional Anesthesia and Pain Medicine. BMJ. doi:10.1097/aap.0000000000000163.
clinicaltrials.govStudy
The Effect of Pectoral Blocks on Perioperative Pain in Gender Affirmation Top Surgery
2020. "The Effect of Pectoral Blocks on Perioperative Pain in Gender Affirmation Top Surgery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04474366.
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top